Related Experiment Video
Updated: Feb 5, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
Katarzyna Drozda1, Michael A Pacanowski1, Christian Grimstein1
1Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Abstract:
The U.S. Food and Drug Administration recently marked 10 years since first updating the labeling for warfarin (often referred to as the "poster child" of pharmacogenomics) to include information regarding the potential impact of CYP2C9 and VKORC1 genetic variation on warfarin dosing requirements and risks. Herein, we opine on the experience updating the warfarin labeling, highlighting more generally the enabling factors and challenges encountered when considering incorporation of pharmacogenomic information into the prescribing recommendations for already approved drugs. We also provide a historical perspective of implemented changes in regulatory policies related to personalized medicine.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Cis-regulatory Sequences
Cis-regulatory Sequences
Drug Control Governance: Regulatory Bodies and Their Impact
Global Regulatory Systems
Labeling Emotion

